Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.39 |
| ▸ | TACR2 | P21452 | 5/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835305 | 0.90 | NAMPT (0.44) | USP2TSHRNAMPTTACR2AVPR1A | |
| SCHEMBL3225529 | 0.90 | USP2 (0.46) | USP2TSHRROCK2NAMPTPOLB | |
| SCHEMBL3232235 | 0.88 | USP2 (0.44) | USP2TSHRROCK2POLBOPRM1 | |
| SCHEMBL3218179 | 0.88 | USP2 (0.43) | USP2TSHRROCK2POLBOPRM1 | |
| SCHEMBL4217950 | 0.87 | USP2 (0.44) | USP2TSHRNAMPTTACR2AVPR1A | |
| SCHEMBL3218367 | 0.87 | USP2 (0.46) | USP2TSHRROCK2NAMPTPOLB | |
| SCHEMBL12249940 | 0.87 | ALDH1A1 (0.49) | USP2TSHRROCK2OPRM1OPRD1 | |
| SCHEMBL4224198 | 0.87 | USP2 (0.47) | USP2TSHRROCK2NAMPTPOLB | |
| SCHEMBL12249981 | 0.86 | USP2 (0.51) | USP2TSHRROCK2NAMPTPOLB | |
| SCHEMBL3235342 | 0.85 | USP2 (0.53) | USP2TSHRROCK2POLBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | disclosed |
| EP-2133339-A1 | NOVEL (2-AMINOPHENYL)PYRIDINECARBOXAMIDE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | USP2 3063/4885TSHR 4241/4885ROCK2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.